Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be "Mast Therapeutics, Inc."...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced its plans to develop ANX-188 in complications of arterial disease, initially as an...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reviewed the platform of data and know-how that supports development of ANX-188 in multiple...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen ...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188. Brian...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 15th...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated patient recruitment in its pivotal phase 3 clinical study of...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the appointment of Brandi L. Roberts to Chief Financial Officer and Senior Vice...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 6th...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that ANX-188 drug product for use in the phase 3 clinical study of ANX-188 (purified...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the launch of its redesigned and updated corporate website,www.adventrx.com. The new...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended September 30, 2012. "With a strong cash...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today provided details regarding the phase 3 clinical study of ANX-188 (purified poloxamer 188) in...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it will hold a conference call at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has engaged Theradex® Systems, Inc., a contract research organization with 30...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Ted W. Love, M.D., has joined its Board of Directors. Dr. Love most recently...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended June 30, 2012. "We start the second half of...
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it is presenting at the 1st Annual Sickle Cell Disease Therapeutics Conference....
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that is has entered into a multi-year agreement with Patheon Inc. under which Patheon ...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company has been invited to participate in and present at the BIO Business...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) and Pierre Fabre Medicament today announced they have entered into a multi-year agreement under which ...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the first quarter ended March 31, 2012. "In the first quarter,...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company is a sponsor of and will be presenting at the Martin Center's 2012...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.